Omalizumab Improves Quality of Life and Asthma Control in Chinese Patients With Moderate to Severe Asthma: A Randomized Phase III StudyWOS
Allergy, asthma & immunology research, Volume 8, Issue 4, 2016, Pages 319-328.
Keywords:AsthmaChinaallergy and immunologyomalizumabquality of life
Omalizumab is the preferred add-on therapy for patients with moderate-to-severe persistent allergic asthma and has demonstrated efficacy and safety in various ethnicities. This study evaluated the efficacy and safety of omalizumab in Chinese patients with moderate-to-severe allergic asthma.This randomized, double-blind, parallel-group, pl...More